Literature DB >> 797668

Improved compatibility of ALG therapy by application of aggregate free globulin.

J Ring, J Seifert, F Seiler, W Brendel.   

Abstract

Horse anti-human lymphocyte globulin (ALG) solutions contain, like human gamma-globulin preparations, a varying amount of IgG aggregates, which increase during longer periods of storage. Aggregate formation does not impair the immunosuppressive potency of ALG, as has been shown by prolongation of skin allograft survival time in primates. Deaggregated ALG, which can be obtained by ultracentrifugation at 100,000 g over 2 h, is less immunogenic than aggregate containing ALG. The clinical compatibility of ALG was significantly improved by ultracentrifugal deaggregation.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 797668     DOI: 10.1159/000231686

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  5 in total

Review 1.  Anaphylactoid reactions to intravenous solutions used for volume substitution.

Authors:  J Ring
Journal:  Clin Rev Allergy       Date:  1991 Fall-Winter

2.  Human blood cells ultrastructural changes and mediator release after exposure to roentgenographic contrast media.

Authors:  M J Fritzler; J Ring; C M Arroyave; E M Tan
Journal:  Can Med Assoc J       Date:  1978-10-21       Impact factor: 8.262

3.  [Problems of intravenous gammaglobulin therapy (author's transl)].

Authors:  J Ring; K H Duswald
Journal:  Klin Wochenschr       Date:  1980-08-15

4.  [Concentration of intravenously administered gammaglobulin preparations in dog skin (author's transl)].

Authors:  J Ring; K H Duswald; T Bachmann; W Stephan; W Brendel
Journal:  Arch Dermatol Res       Date:  1977-12-27       Impact factor: 3.017

5.  In vitro histamine and serotonin release by radiographic contrast media (RCM). Complement-dependent and -independent release reaction and changes in ultrastructure of human blood cells.

Authors:  J Ring; C M Arroyave; M J Frizler; E M Tan
Journal:  Clin Exp Immunol       Date:  1978-04       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.